Beyond static measures: A review of functional magnetic resonance spectroscopy and its potential to investigate dynamic glutamatergic abnormalities in schizophrenia
Restricted accessReview articleFirst published online May, 2018
Beyond static measures: A review of functional magnetic resonance spectroscopy and its potential to investigate dynamic glutamatergic abnormalities in schizophrenia
Abnormalities of the glutamate system are increasingly implicated in schizophrenia but their exact nature remains unknown. Proton magnetic resonance spectroscopy (1H-MRS), while fundamental in revealing glutamatergic alterations in schizophrenia, has, until recently, been significantly limited and thought to only provide static measures. Functional magnetic resonance spectroscopy (fMRS), which uses sequential scans for dynamic measurement of a range of brain metabolites in activated brain areas, has lately been applied to a variety of task or stimulus conditions, producing interesting insights into neurometabolite responses to neural activation. Here, we summarise the existing 1H-MRS studies of brain glutamate in schizophrenia. We then present a comprehensive review of research studies that have utilised fMRS, and lastly consider how fMRS methods might further the understanding of glutamatergic abnormalities in schizophrenia.
AoyamaNThébergeJDrostDJet al. (2011) Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br J Psychiatry198: 448–456.
2.
ApšvalkaDGadieAClemenceMet al. (2015) Event-related dynamics of glutamate and BOLD effects measured using functional magnetic resonance spectroscopy (fMRS) at 3T in a repetition suppression paradigm. NeuroImage118: 292–300.
3.
BarthaR (1997) Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry54: 959–965.
4.
BednarikPTkacIGioveFet al. (2015) Neurochemical and BOLD responses during neuronal activation measured in the human visual cortex at 7 Tesla. J Cereb Blood Flow Metab35: 601–610.
5.
BednarikPTkacIGioveFet al. (2017) Neurochemical responses to chromatic and achromatic stimuli in the human visual cortex. J Cereb Blood Flow Metab1: 271678X17695291.
6.
BlockWBayerTATepestRet al. (2000) Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: A proton magnetic resonance spectroscopy study. Neurosci Lett289: 147–151.
7.
BloemenOJGleichTde KoningMBet al. (2011) Hippocampal glutamate levels and striatal dopamine D(2/3) receptor occupancy in subjects at ultra high risk of psychosis. Biol Psychiatry70: e1–e2, author reply e3.
8.
BustilloJRChenHJonesTet al. (2014) Increased glutamine in patients undergoing long-term treatment for schizophrenia: A proton magnetic resonance spectroscopy study at 3 T. JAMA Psychiatry71: 265–272.
9.
ChangLFriedmanJErnstTet al. (2007) Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: Implication for glial dysfunction. Biol Psychiatry62: 1396–1404.
10.
ChenCSigurdssonHPPepesSEet al. (2017) Activation induced changes in GABA: Functional MRS at 7T with MEGA-sLASER. NeuroImage156: 207–213.
11.
ChiappelliJShiQWijtenburgSAet al. (2017) Glutamatergic response to heat pain stress in schizophrenia. Schizophr Bull. Epub ahead of print. DOI: 10.1093/schbul/sbx133.
12.
CleveMGussewAReichenbachJR (2015) In vivo detection of acute pain-induced changes of GABA+ and Glx in the human brain by using functional 1H MEGA-PRESS MR spectroscopy. NeuroImage105: 67–75.
13.
DagerSRFriedmanSDHeideAet al. (1999) Two-dimensional proton echo-planar spectroscopic imaging of brain metabolic changes during lactate-induced panic. Arch Gen Psychiatry56: 70–77.
de la Fuente-SandovalCLeón-OrtizPAzcárragaMet al. (2013a) Striatal glutamate and the conversion to psychosis: A prospective 1H-MRS imaging study. Int J Neuropsychopharmacol16: 471–475.
16.
de la Fuente-SandovalCLeón-OrtizPAzcárragaMet al. (2013b) Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: A longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry70: 1057–1066.
17.
de la Fuente-SandovalCLeón-OrtizPFavilaRet al. (2011) Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology36: 1781–1791.
18.
DuarteJMNLeiHMlynárikVet al. (2012) The neurochemical profile quantified by in vivo 1H NMR spectroscopy. NeuroImage61: 342–362.
19.
EgertonABruggerSRaffinMet al. (2012) Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology37: 2515–2521.
20.
EgertonAStoneJMChaddockCAet al. (2014) Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis. Neuropsychopharmacology39: 2891–2899.
21.
Floyer-LeaAWylezinskaMKincsesTet al. (2006) Rapid modulation of GABA concentration in human sensorimotor cortex during motor learning. J Neurophysiol95: 1639–1644.
22.
GalińskaBSzulcATarasówEet al. (2009) Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia. Med Sci Monit15: CR82–CR88.
23.
GussewARzannyRErdtelMet al. (2010) Time-resolved functional 1H MR spectroscopic detection of glutamate concentration changes in the brain during acute heat pain stimulation. NeuroImage49: 1895–1902.
24.
GutzeitAMeierDFroehlichJMet al. (2013) Differential NMR spectroscopy reactions of anterior/posterior and right/left insular subdivisions due to acute dental pain. Eur Radiol23: 450–460.
25.
GutzeitAMeierDMeierMLet al. (2011) Insula-specific responses induced by dental pain. A proton magnetic resonance spectroscopy study. Eur Radiol21: 807–815.
26.
HarrisonPJWeinbergerDR (2005) Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry10: 40–68; image 45.
27.
HasanAWobrockTFalkaiPet al. (2014) Hippocampal integrity and neurocognition in first-episode schizophrenia: A multidimensional study. World J Biol Psychiatry15: 188–199.
28.
HennigJ (2012) Functional spectroscopy to no-gradient fMRI. NeuroImage62: 693–698.
29.
HowesOMcCutcheonRStoneJ (2015) Glutamate and dopamine in schizophrenia: An update for the 21st century. J Psychopharmacol29: 97–115.
30.
HuangZDavisHHIVYueQet al. (2015) Increase in glutamate/glutamine concentration in the medial prefrontal cortex during mental imagery: A combined functional mrs and fMRI study. Hum Brain Mapp36: 3204–3212.
31.
HutchesonNLReidMAWhiteDMet al. (2012) Multimodal analysis of the hippocampus in schizophrenia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging. Schizophr Res140: 136–142.
32.
HyderFHermanPBaileyCJet al. (2016) Uniform distributions of glucose oxidation and oxygen extraction in gray matter of normal human brain: No evidence of regional differences of aerobic glycolysis. J Cereb Blood Flow Metab36: 903–916.
33.
IpIBerringtonAHessATet al. (2017) Combined fMRI-MRS acquires simultaneous glutamate and BOLD-fMRI signals in the human brain. NeuroImage155: 113–119.
34.
JavittDC (2007) Glutamate and schizophrenia: Phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol78: 69–108.
35.
KanamoriKRossBDKondratRW (2002) Glial uptake of neurotransmitter glutamate from the extracellular fluid studied in vivo by microdialysis and (13)C NMR. J Neurochem83: 682–695.
36.
KauppinenRAPirttiläTRAuriolaSOet al. (1994) Compartmentation of cerebral glutamate in situ as detected by 1H/13C n.m.r. Biochem J298: 121–127.
37.
KraguljacNVReidMAWhiteDMet al. (2012) Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia. Neuropsychopharmacology37: 2635–2642.
38.
KrystalJHPerryEBGueorguievaRet al. (2005) Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: Implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry62: 985–994.
39.
KuhnSSchubertFMekleRet al. (2016) Neurotransmitter changes during interference task in anterior cingulate cortex: Evidence from fMRI-guided functional MRS at 3 T. Brain Struct Funct221: 2541–2551.
40.
LallyNMullinsPGRobertsMVet al. (2014) Glutamatergic correlates of gamma-band oscillatory activity during cognition: A concurrent ER-MRS and EEG study. NeuroImage85: 823–833.
41.
LinYStephensonMCXinLet al. (2012) Investigating the metabolic changes due to visual stimulation using functional proton magnetic resonance spectroscopy at 7 T. J Cereb Blood Flow Metab32: 1484–1495.
42.
LismanJECoyleJTGreenRWet al. (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci31: 234–242.
43.
LutkenhoffESvan ErpTGThomasMAet al. (2010) Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry15: 308–318.
44.
MagistrettiPJPellerinLRothmanDLet al. (1999). Energy on demand. Science283: 496–497.
45.
MangiaSTkácIGruetterRet al. (2006) Sensitivity of single-voxel 1H-MRS in investigating the metabolism of the activated human visual cortex at 7 T. Magn Reson Imaging24: 343–348.
46.
MangiaSTkácIGruetterRet al. (2007) Sustained neuronal activation raises oxidative metabolism to a new steady-state level: Evidence from 1H NMR spectroscopy in the human visual cortex. J Cereb Blood Flow Metab27: 1055–1063.
47.
MarsmanAvan den HeuvelMPKlompDWJet al. (2013) Glutamate in schizophrenia: A focused review and meta-analysis of ¹H-MRS studies. Schizophr Bull39: 120–129.
48.
MasonGFGruetterRRothmanDLet al. (1995) Simultaneous determination of the rates of the TCA cycle, glucose utilization, alpha-ketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. J Cereb Blood Flow Metab15: 12–25.
49.
MasonGFPanJWPonderSLet al. (1994) Detection of brain glutamate and glutamine in spectroscopic images at 4.1 T. Magn Reson Med32: 142–145.
50.
McKennaMCWaagepetersenHSSchousboeAet al. (2006) Neuronal and astrocytic shuttle mechanisms for cytosolic-mitochondrial transfer of reducing equivalents: Current evidence and pharmacological tools. Biochem Pharmacol71: 399–407.
51.
MekleRKuhnSPfeifferHet al. (2017) Detection of metabolite changes in response to a varying visual stimulation paradigm using short-TE 1 H MRS at 7 T. NMR Biomed 30. DOI: 10.1002/nbm.3672.
52.
MerrittKEgertonAKemptonMJet al. (2016) Nature of glutamate alterations in schizophrenia. JAMA Psychiatry52: 998–1007.
53.
MichelsLMartinEKlaverPet al. (2012) Frontal GABA levels change during working memory. PLoS One7: e31933.
54.
MinzenbergMJLairdARThelenSet al. (2009) Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry66: 811–822.
55.
MullinsPGChenHXuJet al. (2008) Comparative reliability of proton spectroscopy techniques designed to improve detection of J-coupled metabolites. Magn Reson Med60: 964–969.
56.
MullinsPGRowlandLMJungREet al. (2005) A novel technique to study the brain’s response to pain: Proton magnetic resonance spectroscopy. NeuroImage26: 642–646.
57.
NeufieldRWJBoksmanKVollickDet al. (2010) Stochastic dynamics of stimulus encoding in schizophrenia: Theory, testing, and application. J Math Psychol54: 90–108.
58.
OhrmannPSiegmundASuslowTet al. (2005) Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: A proton magnetic resonance spectroscopy study. Schizophr Res73: 153–157.
59.
OlneyJWNewcomerJWFarberNB (1999) NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res33: 523–533.
60.
PoelsEMKegelesLSKantrowitzJTet al. (2014) Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings. Schizophr Res152: 325–332.
61.
PrichardJRothmanDNovotnyEet al. (1991) Lactate rise detected by 1H NMR in human visual cortex during physiologic stimulation. Proc Natl Acad Sci USA88: 5829–5831.
62.
ReidMAStoeckelLEWhiteDMet al. (2010) Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry68: 625–633.
63.
RichardsTL (2001) Functional magnetic resonance imaging and spectroscopic imaging of the brain: Application of fMRI and fMRS to reading disabilities and education. Learn Disabil Q24: 189–204.
64.
RodrigoRFelipoV (2007) Control of brain glutamine synthesis by NMDA receptors. Front Biosci12: 883–890.
65.
RothmanDLBeharKLHyderFet al. (2003) In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: Implications for brain function. Annu Rev Physiol65: 401–427.
66.
RowlandLMBustilloJRMullinsPGet al. (2005) Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: A 4-T proton MRS study. Am J Psychiatry162: 394–396.
67.
RowlandLMKontsonKWestJet al. (2013) In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull39: 1096–1104.
68.
SchallerBMekleRXinLet al. (2013) Net increase of lactate and glutamate concentration in activated human visual cortex detected with magnetic resonance spectroscopy at 7 Tesla. J Neurosci Res91: 1076–1083.
69.
SchallerBXinLO’BrienKet al. (2014) Are glutamate and lactate increases ubiquitous to physiological activation? A (1)H functional MR spectroscopy study during motor activation in human brain at 7Tesla. NeuroImage93: 138–145.
70.
ShenJPetersenKFBeharKLet al. (1999) Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Proc Natl Acad Sci96: 8235–8240.
71.
ShulmanRGHyderFRothmanDL (2009) Baseline brain energy supports the state of consciousness. Proc Natl Acad Sci106: 11096–11101.
72.
SnyderJWilmanA (2010) Field strength dependence of PRESS timings for simultaneous detection of glutamate and glutamine from 1.5 to 7T. J Magn Reson203: 66–72.
73.
StaggCJBestmannSConstantinescuAOet al. (2011) Relationship between physiological measures of excitability and levels of glutamate and GABA in the human motor cortex. J Physiol589: 5845–5855.
74.
StanleyJABurgessAKhatibDet al. (2017) Functional dynamics of hippocampal glutamate during associative learning assessed with in vivo 1H functional magnetic resonance spectroscopy. NeuroImage153: 189–197.
75.
StoneJMDayFTsagarakiHet al. (2009) Glutamate dysfunction in people with prodromal symptoms of psychosis: Relationship to gray matter volume. Biol Psychiatry66: 533–539.
76.
StoneJMDietrichCEddenRet al. (2012) Ketamine effects on brain GABA and glutamate levels with 1H-MRS: Relationship to ketamine-induced psychopathology. Mol Psychiatry17: 664–665.
77.
StoneJMMorrisonPDPilowskyLS (2007) Glutamate and dopamine dysregulation in schizophrenia: A synthesis and selective review. J Psychopharmacol21: 440–452.
78.
SzulcAGalinskaBTarasowEet al. (2011) Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment. Pharmacopsychiatry44: 148–157.
79.
TaylorRNeufeldRWJSchaeferBet al. (2015a) Functional magnetic resonance spectroscopy of glutamate in schizophrenia and major depressive disorder: Anterior cingulate activity during a color-word Stroop task. NPJ Schizophr1: 15028.
80.
TaylorRSchaeferBDensmoreMet al. (2015b) Increased glutamate levels observed upon functional activation in the anterior cingulate cortex using the Stroop task and functional spectroscopy. Neuroreport26: 107–112.
81.
TayoshiSYSumitaniSTaniguchiKet al. (2009) Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr Res108: 69–77.
82.
ThébergeJAl-SemaanYWilliamsonPCet al. (2003) Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry160: 2231–2233.
83.
ThébergeJBarthaRDrostDJet al. (2002) Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry159: 1944–1946.
84.
ThébergeJWilliamsonKEAoyamaNet al. (2007) Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry191: 325–334.
85.
TibboPHanstockCValiakalayilAet al. (2004) 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry161: 1116–1118.
86.
TibboPGBernierDHanstockCCet al. (2013) 3-T proton magnetic spectroscopy in unmedicated first episode psychosis: A focus on creatine. Magn Reson Med69: 613–620.
87.
UrrilaASHakkarainenAHeikkinenSet al. (2003) Metabolic imaging of human cognition: An fMRI/1H-MRS study of brain lactate response to silent word generation. J Cereb Blood Flow Metab23: 942–948.
88.
UrrilaASHakkarainenAHeikkinenSet al. (2004) Stimulus-induced brain lactate: Effects of aging and prolonged wakefulness. J Sleep Res13: 111–119.
89.
Van ElstLTValeriusGBüchertMet al. (2005) Increased prefrontal and hippocampal glutamate concentration in schizophrenia: Evidence from a magnetic resonance spectroscopy study. Biol Psychiatry58: 724–730.
90.
WijtenburgSAKnight-ScottJ (2011) Very short echo time improves the precision of glutamate detection at 3T in 1H magnetic resonance spectroscopy. J Magn Reson Imaging34: 645–652.
91.
WijtenburgSAWrightSNKorenicSAet al. (2017) Altered glutamate and regional cerebral blood flow levels in schizophrenia: A 1H-MRS and pCASL study. Neuropsychopharmacology42: 562–571.
92.
WijtenburgSAYangSFischerBAet al. (2015) In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: Application to schizophrenia. Neurosci Biobehav Rev51: 276–295.
93.
WoodSJYücelMWellardRMet al. (2007) Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: A proton magnetic resonance spectroscopy study at 3 T. Schizophr Res94: 328–331.
94.
YamasueHFukuiTFukudaRet al. (2003) Drug-induced parkinsonism in relation to choline-containing compounds measured by 1H-MR spectroscopy in putamen of chronically medicated patients with schizophrenia. Int J Neuropsychopharmacol6: 353–360.
